Polymerases, compositions, and methods of use

Patent metadata

Field	Value
Publication number	US-11634697-B2
Application number	US-202117226393-A
Country	US
Kind code	B2
Filing date	Apr 9, 2021
Priority date	Dec 5, 2018
Publication date	Apr 25, 2023
Grant date	Apr 25, 2023

Abstract

Presented herein are altered polymerase enzymes for improved incorporation of nucleotides and nucleotide analogues, in particular altered polymerases that maintain high fidelity under reduced incorporation times, as well as methods and kits using the same.

First claim

The invention claimed is:

1. A recombinant altered DNA polymerase comprising an amino acid sequence that is at least 80% identical to the 9° N DNA polymerase amino acid sequence comprising SEQ ID NO:1, wherein the DNA polymerase comprises at least one amino acid substitution mutation at a position functionally equivalent to Ala281, Phe283, Thr349, or Trp397 in the 9° N DNA polymerase amino acid sequence, further comprising an amino acid substitution mutation at a position functionally equivalent to Tyr497 and at least one amino acid substitution mutation at a position functionally equivalent to Arg247, Glu599, or His633 in the 9° N DNA polymerase amino acid sequence.

2. The polymerase of claim 1 , wherein the substitution mutation at the position functionally equivalent to Tyr497 comprises a mutation to a non-polar, hydrophobic, or uncharged amino acid.

3. The polymerase of claim 2 , wherein the substitution mutation at the position functionally equivalent to Tyr497 comprises a mutation to Gly.

4. The polymerase of claim 1 , wherein the substitution mutation at the position functionally equivalent to Arg247 comprises a mutation to a polar or uncharged amino acid.

5. The polymerase of claim 4 , wherein the substitution mutation at the position functionally equivalent to Arg247 comprises a mutation to Tyr.

6. The polymerase of claim 1 , wherein the substitution mutation at the position functionally equivalent to Glu599 comprises a mutation to a polar amino acid.

7. The polymerase of claim 6 , wherein the substitution mutation at the position functionally equivalent to Glu599 comprises a mutation to Asp.

8. The polymerase of claim 1 , wherein the substitution mutation at the position functionally equivalent to His633 comprises a mutation to a non-polar, hydrophobic, or uncharged amino acid.

9. The polymerase of claim 8 , wherein the substitution mutation at the position functionally equivalent to His633 comprises a mutation to Gly.

10. The polymerase of claim 1 , wherein the polymerase comprises at least two or three amino acid substitution mutations at positions functionally equivalent to an amino acid selected from Arg247, Glu599, or His633 in the 9° N DNA polymerase amino acid sequence.

11. The polymerase of claim 1 , further comprising at least one amino acid substitution mutation at a position functionally equivalent to Lys620 or Val661 in the 9° N DNA polymerase amino acid sequence.

12. The polymerase of claim 11 , wherein the substitution mutation at the position functionally equivalent to Lys620 comprises a mutation to a polar amino acid.

13. The polymerase of claim 12 , wherein the substitution mutation at the position functionally equivalent to Lys620 comprises a mutation to Arg.

14. The polymerase of claim 11 , wherein the substitution mutation at the position functionally equivalent to Val661 comprises a mutation to a polar amino acid.

15. The polymerase of claim 14 , wherein the substitution mutation at the position functionally equivalent to Val661 comprises a mutation to Asp.

16. The polymerase of claim 11 , wherein the polymerase comprises at least two, at least three, at least four, or at least five amino acid substitution mutations at positions functionally equivalent to an amino acid selected from Arg247, Glu599, His633, Lys620, or Val661 in the 9° N DNA polymerase amino acid sequence, and wherein at least one of the amino acid substitution mutation is selected from Arg247, Glu599, His633 and at least one of the amino acid substitution mutations is selected from Lys620, or Val661.

17. The polymerase of claim 1 , wherein the polymerase further comprises amino acid substitution mutations at positions functionally equivalent to amino acids Met129, Asp141, Glu143, Cys223, Leu408, Tyr409, Pro410, or Ala485 in the 9° N DNA polymerase amino acid sequence.

18. The polymerase of claim 1 , wherein the polymerase is a family B type DNA polymerase.

19. The polymerase of claim 18 , wherein the polymerase is selected from the group consisting of a family B archaeal DNA polymerase, a human DNA polymerase-a, T4 polymerase, RB69 polymerase, and phi29 phage DNA polymerase.

20. The polymerase of claim 19 , wherein the family B archaeal DNA polymerase is from a genus selected from the group consisting of Thermococcus, Pyrococcus , and Methanococcus.

Assignees

• Illumina Inc
• Illumina Cambridge Ltd
• Illumina Singapore Pte Ltd

Inventors

• Klausing Kay
• Ghomi Hamed Tabatabaei
• Golynskiy Misha
• Nirantar Saurabh
• Mcdonald Seth
• Peisajovich Sergio

Classifications

• C12N9/1252 Primary

  DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

• C12Y207/07007

  DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

• C12Q2563/107

  fluorescence · CPC title

• C12N15/52

  Genes encoding for enzymes or proenzymes · CPC title

• C12Q1/68

  involving nucleic acids · CPC title